Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $388000.0.

  • Champions Oncology's Change in Accured Expenses rose 18321.17% to $388000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was -$46000.0, marking a year-over-year decrease of 12190.48%. This contributed to the annual value of $395000.0 for FY2025, which is 46238.53% up from last year.
  • Champions Oncology's Change in Accured Expenses amounted to $388000.0 in Q4 2025, which was up 18321.17% from -$755000.0 recorded in Q3 2025.
  • Champions Oncology's 5-year Change in Accured Expenses high stood at $405000.0 for Q1 2024, and its period low was -$755000.0 during Q3 2025.
  • Its 5-year average for Change in Accured Expenses is $7400.0, with a median of -$15500.0 in 2024.
  • Per our database at Business Quant, Champions Oncology's Change in Accured Expenses surged by 30447.76% in 2024 and then plummeted by 109841.27% in 2025.
  • Champions Oncology's Change in Accured Expenses (Quarter) stood at -$70000.0 in 2021, then tumbled by 310.0% to -$287000.0 in 2022, then soared by 76.66% to -$67000.0 in 2023, then surged by 304.48% to $137000.0 in 2024, then skyrocketed by 183.21% to $388000.0 in 2025.
  • Its last three reported values are $388000.0 in Q4 2025, -$755000.0 for Q3 2025, and $289000.0 during Q2 2025.